Nachrichten zur Apellis Pharmaceuticals Inc. Aktie

Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Apellis Pharmaceuticals Q3 2023 Earnings Preview

…

Investigation Alert Apellis Pharmaceuticals, KeyCorp, RTX Corporation, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) …

Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earnings

…

Apellis Pharmaceuticals: Eye Watering, Roller-Coaster Ride In 2023 To Date - Im Hitting Pause

…

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet…

Sobi announces positive Phase 2 NOBLE results of pegcetacoplan in post-transplant recurrence of primary IC-MPGN and C3G

· After 12 weeks, 50% of patients treated with pegcetacoplan showed a reduction in C3c staining by two or more…

Apellis Pharmaceuticals raised at JPMorgan as improving Syfovre fundamentals will be upside driver for shares By Investing.com

Apellis Pharmaceuticals raised at JPMorgan as improving Syfovre fundamentals will be upside driver for shares…

Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023

WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today provided an update on…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food…

Lifshitz Law PLLC Announces Investigations of Apellis Pharmaceutics, Inc. (NASDAQ: APLS), RTX Corp. (NYSE: RTX), Live Nation Entertainment, Inc. (NYSE: LYV), and KeyCorp (NYSE: KEY)

NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)…

APLS DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS

NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Apellis Pharmaceuticals, Inc. - APLS

CEDARHURST, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:…

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)

LOS ANGELES, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the…

ROSEN, A LEADING AND RANKED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023

WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S.…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Apellis, Party City, and Hayward and Encourages Investors to Contact the Firm

NEW YORK, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc.…

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Apellis Pharmaceuticals, Inc. - APLS

CEDARHURST, N.Y., Sept. 20, 2023 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues…

: Apellis Pharmaceuticals shares rally as competing eye treatment fails to impress analysts

Apellis Pharmaceuticals Inc. shares APLS jumped 8% premarket on Tuesday after competitor Iveric Bio, a unit of Astellas Pharma Inc.…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)

NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

Apellis Pharmaceuticals konzentriert sich nun weiterhin auf dem großen Hoffnungsträger Syfovre - Aktienanalyse

Schwarzach am Main (www.aktiencheck.de) - Apellis Pharmaceuticals-Aktienanalyse von "ZertifikateJournal": Der Schock sitzt den Aktionären von Apellis Pharma (ISIN: US03753U1060, WKN: A2JAAW,…

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Apellis Pharmaceuticals, Inc. - APLS

CEDARHURST, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)

NEW YORK, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)

LOS ANGELES, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eos, Apellis, and Party City and Encourages Investors to Contact the Firm

NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.

NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

NEW YORK, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS

NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)

NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics

Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog....…

dpa-AFX ProFeed